ABSTRACT
Objective: To prepare Compound Xiongqi Maichong Tablets (CXMT) by selecting ligustrazine and Panax notoginseng saponins (PNS) in the treatment of coronary heart disease as a model drug, using hypromellose (HPMC) as coating material, and control of drug release delay as 4 h. Methods: The core system of CXMT was prepared by direct powder compression method; The best coating prescription and preparation of CXMT by press coated was optimized by central composite design and response surface method. The release model was fitted by DDsolver software, and the synchronous release of drug was studied. Results: The in vitro cumulative release fitting order of CXMT preparation was Logistic > Higuchi; Logistic model fitting degree was 0.950 1, and AIC was 29.432 0. So the drug release mechanism of CXMT was type S dissolution process, and the in vitro cumulative release model was the Logistic model. Conclusion: Through the study of CXMT preparation technology and the drug release mechanism, the quality of the prepared CXMT is stable, and the lag time is 4 h; Different components of the cumulative dissolution rate are over 90%, which reach the pulse drug release standard.